Go to the list of all blogs
Harry Richardson's Avatar
published in Blogs
Apr 23, 2026

FormFactor (FORM): +45% Rally on AI Testing Strength Ahead of Q1 Earnings

Key Takeaways

  • FormFactor shares have surged significantly in recent weeks, driven by robust demand for its semiconductor testing solutions in AI applications.
  • Upcoming first-quarter 2026 earnings on April 29 represent a pivotal catalyst for further price movement.
  • Analyst sentiment is mixed, with recent price target adjustments reflecting valuation concerns amid the rally.
  • Strong positioning in high-bandwidth memory (HBM) testing and probe cards benefits from AI chip growth.
  • Semiconductor-focused AI trading bots show impressive performance stats, highlighting sector momentum.

Current Market Snapshot

From what I see, FORM stock has built impressive upward momentum in recent weeks, pushing toward 52-week highs as investors grow optimistic about its role in semiconductor testing for AI and advanced computing. Heightened trading activity and positive sector sentiment have lifted valuation multiples, particularly with demand ramping up for high-performance probe cards. Broader trends in semiconductors, fueled by AI-driven chip innovation, have underpinned this move, even as mixed analyst views call for some caution. In my view, this makes FORM a notable player in the current market cycle for those following technology growth shifts. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Recent Developments Driving FORM Price Action

FORM stock has rallied sharply over the past 30 days, up approximately +45% and touching new 52-week highs near $152, largely due to rising demand for its probe card and analytical probing solutions in AI chip production. This mirrors enthusiasm across the semiconductor space, where peers like Amkor Technology, Entegris, and Kulicke & Soffa have also gained ground amid the AI infrastructure buildout.

On April 8, FormFactor announced its first-quarter 2026 financial results release for April 29, along with a conference call, building anticipation following its prior quarter's strong performance in high-bandwidth memory (HBM) testing revenue. The company guided Q1 EPS at $0.41-$0.49, signaling continued strength from AI-related orders. This helped drive intraday gains, as investors positioned ahead of potential insights into HBM and cryogenic probing demand.

Analysts responded to the rally in varied ways. Cantor Fitzgerald raised its price target to $125 from $100 on April 6, pointing to favorable sector dynamics, while Argus lifted its target to $135 but kept a hold rating. B. Riley Securities, however, downgraded FORM to neutral from buy on April 13, citing elevated valuations after the run-up, with a $130 target. Consensus targets sit around $96-$100, suggesting caution even with buy ratings elsewhere.

On March 25, Rohde & Schwarz joined FormFactor's partner ecosystem, which should enhance its quantum computing offerings through better test solutions and add to positive sentiment in advanced tech. Insider activity featured CEO Mike Slessor’s sale on April 15—typical profit-taking after a 162% YTD gain, though it drew some attention. Macro tailwinds, including a semiconductor rebound from AI data center growth and easing geopolitical tensions, fueled a 14% weekly advance as of mid-April. Coverage naming FORM a "top momentum pick" and AI enabler boosted retail interest, tempered somewhat by valuation worries from sources like GuruFocus. Overall, these factors tie FORM's AI testing strengths to clear bullish price action, backed by volume surges.

AI Trading Bots Highlighting Semiconductor Momentum

One thing that stands out to me when analyzing sectors like semiconductors is the performance of AI-driven tools, and I regularly check Tickeron’s Trending AI Robots page. It curates the top 25 performers from a library of 351 AI trading bots that apply diverse strategies across thousands of tickers in stocks, ETFs, and crypto. These bots use AI and machine learning for real-time signals, covering swing trading, short-term scalping, and sector plays with timeframes from 5 minutes to days. Semiconductor standouts include "Semiconductors SOXL" with a +94.85% annualized return, 67.76% win rate, and 1.84 profit factor; "LRCX, TER, AMAT, KLAC, AMKR, ASML" at +97.74% annualized return and 3.44 profit factor; and "NVDA, AVGO, AMD, TSM, MU" with +68.27% returns and 59.06% win rate. Win rates generally fall between 56-68%, profit factors 1.5-3.4, and profit-to-drawdown ratios top 4 for the leaders. Designed for today's volatility, they include copy-trading with risk controls, which helps me align with fast-moving markets like this one.

2026 Outlook and Key Factors to Monitor

Looking at 2026 for FormFactor, I'm watching sustained AI chip demand closely, especially HBM adoption in next-generation GPUs and memory stacks, where its probe cards provide a clear advantage. Advances in quantum computing, supported by partners like Rohde & Schwarz, could drive niche growth, as could cryogenic probing for high-performance computing. Supply chain elements in semiconductors—such as equipment lead times and raw material costs—will matter amid foundry capacity expansions.

Risks to consider include valuation pullbacks if AI enthusiasm cools or if smartphone/PC markets stay weak, plus competition from other testing firms. Export controls on advanced tech and macro factors like interest rates could affect capex. The upcoming earnings should shed light on revenue diversification beyond AI, while analyst updates on full-year EPS growth—around $0.90—will provide clues. Keeping tabs on these will help navigate this dynamic space.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations

Related Ticker: FORM

Contributor

Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.


FORM in upward trend: price rose above 50-day moving average on September 17, 2026

FORM moved above its 50-day moving average on September 17, 2026 date and that indicates a change from a downward trend to an upward trend. In 34 of 41 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 83%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on September 08, 2026. You may want to consider a long position or call options on FORM as a result. In 75 of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.

The Moving Average Convergence Divergence (MACD) for FORM just turned positive on September 09, 2026. Looking at past instances where FORM's MACD turned positive, the stock continued to rise in 40 of 51 cases over the following month. The odds of a continued upward trend are 78%.

The 10-day moving average for FORM crossed bullishly above the 50-day moving average on September 21, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 15 of 19 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 79%.

Following a +10.02% 3-day Advance, the price is estimated to grow further. Considering data from situations where FORM advanced for three days, in 237 of 302 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.

Bearish Trend Analysis

The 10-day RSI Indicator for FORM moved out of overbought territory on September 24, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 36 similar instances where the indicator moved out of overbought territory. In 26 of the 36 cases, the stock moved lower in the following days. This puts the odds of a move lower at 72%.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where FORM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 70%.

FORM broke above its upper Bollinger Band on September 23, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for FORM entered a downward trend on September 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. FORM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 40 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 63, placing this stock slightly better than average.

The Tickeron Seasonality Score of 45 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 67 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 77 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.074) is normal, around the industry mean (8.033). P/E Ratio (88.993) is within average values for comparable stocks, (159.834). FORM's Projected Growth (PEG Ratio) (1.500) is slightly higher than the industry average of (0.816). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (9.200) is also within normal values, averaging (27.897).

Notable companies

The most notable companies in this group are Lam Research Corp (NASDAQ:LRCX), Applied Materials (NASDAQ:AMAT), KLA Corporation (NASDAQ:KLAC), Teradyne (NASDAQ:TER), Ambarella (NASDAQ:AMBA).

Industry description

The electronic production equipment industry makes equipment used to produce semiconductors. Such equipment includes wafer fabrication, plasma etching and photo-resist processing equipment. The industry also makes chemical vapor deposition processing systems and photomasks, which are high-purity quartz plates that contain patterns to define integrated circuits layouts. Applied Materials, Inc., Lam Research Corporation, and KLA-Tencor Corporation are examples of electronic production equipment manufacturing companies.

Market Cap

The average market capitalization across the Electronic Production Equipment Industry is 62.72B. The market cap for tickers in the group ranges from 326.86K to 657.13B. ASMLF holds the highest valuation in this group at 657.13B. The lowest valued company is AVSR at 326.86K.

High and low price notable news

The average weekly price growth across all stocks in the Electronic Production Equipment Industry was 5%. For the same Industry, the average monthly price growth was 1%, and the average quarterly price growth was 29%. COHU experienced the highest price growth at 16%, while TRT experienced the biggest fall at -35%.

Volume

The average weekly volume growth across all stocks in the Electronic Production Equipment Industry was -16%. For the same stocks of the Industry, the average monthly volume growth was 11% and the average quarterly volume growth was -44%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 63
P/E Growth Rating: 35
Price Growth Rating: 47
SMR Rating: 71
Profit Risk Rating: 62
Seasonality Score: -33 (-100 ... +100)
View a ticker or compare two or three
FORM
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a manufacturer of semiconductor wafer probe card products

Industry ElectronicProductionEquipment

Industry
Electronic Production Equipment
Address
7005 Southfront Road
Phone
+1 925 290-4000
Employees
2153
Web
https://www.formfactor.com
Interact to see
Advertisement
INSM shares are surging approximately +10% in premarket trading on Monday, March 23, 2026, from a prior close of $136.00, placing the premarket price near $149.60. The primary catalyst is the release of positive topline results from the Phase 3 ENCORE trial of ARIKAYCE® in patients with newly diagnosed or recurrent MAC (Mycobacterium avium complex) lung disease — a readout Insmed had flagged as expected in "March or April 2026".
CF shares are trading approximately -6% lower in Monday's premarket session, dropping from a Friday close of $124.90 to approximately $117.41. Primary catalyst: President Trump announced a five-day pause on strikes against Iranian energy infrastructure following "very good" diplomatic signals, triggering a sharp unwind of the geopolitical risk premium embedded in fertilizer stocks.
APGE shares surged approximately 16% in premarket trading on March 23, 2026, after the company announced positive 52-week data from Part A of its Phase 2 APEX clinical trial. The primary catalyst is a highly anticipated clinical readout showing that zumilokibart (APG777) delivered durable and deepening responses in patients with moderate-to-severe atopic dermatitis at both every 3-month and 6-month dosing intervals.
Shares of VALN are plummeting approximately 35% in Monday's session, from a Friday close of $10.66 to roughly $6.93, in heavy volume trading. The primary catalyst is the release of Phase 3 VALOR trial topline results for Valneva's Lyme disease vaccine candidate, co-developed with PFE (Pfizer) — results that showed strong clinical efficacy but failed to meet the pre-determined statistical criterion for the primary endpoint.
AXTI is surging approximately +11.00% in Monday's session, trading near $60.21, up from a prior closing price of $54.24. The move extends the stock's post-earnings rally that began last Thursday when shares jumped more than 19% following AXT's Q4 2025 results.
Tower Semiconductor (TSEM) shares are surging approximately +10% intraday on Monday, March 23, trading around $180, up from the previous close of $163.63 on March 20, 2026. The primary catalyst is the opening day of APEC 2026 in San Antonio, Texas, where Tower Semiconductor is presenting its newly unveiled Gen3 BCD power management platform designed to address escalating AI data center power demands.
CD is indicated down about 17% in premarket trading after the latest completed session, pointing to a sharp negative market reaction heading into the open. The stock’s weakness comes against a backdrop of lingering uncertainty following its privatization and delisting process from Nasdaq, which has left limited liquidity and a thinner news flow around the name.
SEDG is indicated down roughly 9% in premarket trading, following a strong advance in the prior regular session. The pullback comes after shares rallied on optimism around new product launches and an analyst upgrade, leaving the stock vulnerable to profit-taking and volatility.
NTGR shares surged approximately 11% in premarket trading on March 24, 2026, building on a roughly 20% overnight jump in the prior session. The primary catalyst is a landmark Federal Communications Commission (FCC) ruling that prohibits all imports of consumer routers manufactured overseas, citing national security concerns.
ANNA is surging approximately +20.00% in Tuesday's premarket session, rebounding sharply from Monday's -22.84% decline. The primary catalyst remains the ongoing U.S.-Iran military conflict, which disrupted Qatari LNG exports and drove European benchmark natural gas prices to multi-year highs.
Concentrix Corporation (CNXC) shares are falling approximately 11% in Tuesday's premarket session after the company released its fiscal Q1 2026 earnings report before market open. Adjusted diluted EPS came in at $2.61, missing the Wall Street consensus estimate of approximately $2.64.
Shares of Karyopharm Therapeutics (KPTI) are trading approximately 12% lower in Tuesday's premarket session, with the previous close at $7.63. The primary catalyst is the March 24 release of topline Phase 3 SENTRY trial data, in which the company met only one of two co-primary endpoints.
IBRX shares are down approximately 23% in Tuesday's session, trading near $7.24 after closing at $9.40 on Monday, March 23. The sharp decline follows an 11%+ surge in the prior session, with profit-taking and valuation pressure cited as primary triggers.
Shares of Circle Internet Group (CRCL) are down approximately 9% in Tuesday morning trading, extending a pullback from recent multi-month highs above $126. The primary catalyst appears to be a broad crypto-sector risk-off wave, with Bitcoin sliding below $69,000 and the Fear & Greed Index dropping to extreme fear territory.
ALM shares are indicated down about 11% in early Tuesday trading after closing the prior session at $16.93. The move comes after a powerful multi‑month rally that took the stock from below $3 to an intraday high of $22.55 earlier in March, leaving it vulnerable to profit-taking and volatility.​
LUNR shares are indicated down about 7% in Tuesday premarket trading after closing the last regular session at $20.31. The pullback follows a powerful rally driven by strong 2026 revenue guidance of $900 million–$1 billion and upbeat analyst commentary, including price target hikes and buy ratings.
MAZE shares are trading approximately 27% lower in premarket on March 25, 2026, after the company reported its highly anticipated Phase 2 HORIZON trial topline data for lead drug candidate MZE829. The catalyst is a dual announcement: Phase 2 clinical data for MZE829 in APOL1-mediated kidney disease (AMKD) alongside Q4 and full-year 2025 financial results.
ARM shares surged approximately +10% in premarket trading on March 25, 2026, hitting $148.6 from a prior close of approximately $135. The primary catalyst is Arm's historic strategic pivot: the company announced it will begin selling its own self-developed AGI CPU chips, breaking its decades-long "IP licensing only" business model.
Shares of Enliven Therapeutics (ELVN) are surging approximately +15% in premarket trading on March 25, 2026, driven by renewed investor enthusiasm around the company's advancing clinical program for ELVN-001 in chronic myeloid leukemia (CML). The stock's prior closing price on March 24, 2026 was $31.15, placing the premarket indicated price near $35.82.
AVXL shares are down approximately 29% in premarket trading on Wednesday, March 25, 2026, falling to roughly $2.97 from the prior close of $4.19. The primary catalyst is Anavex's formal withdrawal of its marketing authorization application (MAA) for blarcamesine from the European Union, announced in the early hours of March 25, 2026.